|
Biological Activity:
Selective inhibitor of phosphodiesterase-4 (PDE4)
References: online 1, 2, 3
D.C. Grootendorst et al. Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). Pulmonary Pharmacol. Ther. 16 (2003) 341–347.
P. Norman. PDE4 inhibitors: sustained patenting activity as leading drugs near the market. Exp. Opin. Ther. Pat.2000, 10, 9, 1415-1427.
D.C. Grootendorst, K.F. Rabe. Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Mechanisms in allergy and adult asthma. Cur. Opin. Aller. Clin. Immunol. 2002, 2(1), 61-67.
Chemical Name: Methanesulfonic acid 2-(2,4-dichloro-benzoyl)-3-ureido-benzofuran-6-yl ester
|